Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Overview
Date Founded

1997

Headquarters

No. 7 Kunlunshan Road,Economic & Technological Devt Zone,Lianyungang, Jiangsu 222000

Type of Company

Public

Employees (Worldwide)

24.4K

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology
Wholesale: Consumer Non-Durables/Sundries

Company Description

Jiangsu Hengrui Medicine Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The firm’s products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection, including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections, including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; and film and gel. The company was founded in 1970 and is headquartered in Lianyungang, China.

Contact Data
Trying to get in touch with decision makers at Jiangsu Hengrui Medicine Co., Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

President

Chief Financial Officer & Chief Accountant

Director & Deputy General Manager

Deputy General Manager

Director & Deputy General Manager

Director & Deputy General Manager

Deputy General Manager & Vice President

Deputy General Manager & Vice President

Board of Directors

Independent Director at Jiangsu Hengrui Medicine Co., Ltd.

President at Jiangsu Hengrui Medicine Co., Ltd.

Director & Deputy General Manager at Jiangsu Hengrui Medicine Co., Ltd.

Director & Deputy General Manager at Jiangsu Hengrui Medicine Co., Ltd.

Director & Deputy General Manager at Jiangsu Hengrui Medicine Co., Ltd.

Independent Director at Jiangsu Hengrui Medicine Co., Ltd.

Independent Director at Jiangsu Hengrui Medicine Co., Ltd.

Board Secretary at Jiangsu Hengrui Medicine Co., Ltd.

Paths to Jiangsu Hengrui Medicine Co., Ltd.
Potential Connections via
Relationship Science
You
Jiangsu Hengrui Medicine Co., Ltd.
Owners & Shareholders
Details Hidden

GF seeks to achieve excess absolute returns by adhering to a sustainable profit model and conducting fundamental research to select stocks.

Details Hidden

EFM is a research-driven, value-oriented manager which combines active and passive investment approaches to implement in their equity and fixed income strategies. The firm’s Active Equity Investment philosophy strives to discover value on the basis of in-depth research and pursuing long-term and stable excess returns. They currently have four key product strategies to cater for clients with varied risk tolerance and return expectation: Value, Balanced growth, High growth concentration, and Sector funds. EFM’s Passive Equity strategy utilize full replication and enhanced quantitative techniques with a flexible trading model which covers investment spectrum of large-, mid- and small-cap stocks. The firm currently manages over 50% of its fixed income assets for institutional investors. Their Fixed Income strategy uses in-depth research and a combination of top-down and bottom-up approaches to manage risks for clients and creates continuous and stable values.

Details Hidden

CIC-IM select investments based on established investment principles and values, investing across sectors and geographies. They do not seek control of the companies in their portfolio. The firm pursues investments based on in-depth research within their asset allocation framework to ensure a prudent and disciplined decision-making process. Investment authorization plans are formulated to grant discretionary authority to investment teams to enhance the efficiency and quality of investment decision-making and to clarify project management responsibilities.

Recent Transactions
Details Hidden

Jiangsu Hengrui Medicine Co., Ltd. purchases Beijing Hengsen Innovative Pharmaceutical Technology Co. Ltd.

Details Hidden

Lianyungang Sipai Industrial Co. Ltd. purchases Lianyungang Huachen Medicine Co. Ltd. from Jiangsu Hengrui Medicine Co., Ltd.

Details Hidden

Lianyungang Kangmei Property Co., Ltd. purchases Jiangsu Hengrui Human Resources Co., Ltd. from Jiangsu Hengrui Medicine Co., Ltd.

Clients

Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the manufacture and sale of Chinese herbal medicine and bio pharmceuitical products. Its business segments include pharmaceutical production & development, medical services, and medicine distribution sectors. Its products include medicines for cardiovascular, digestive system, tumor & immune regulation, cold medication, gynaecological treatment, anti-infective drugs, endocrine, blood system and urinary system diseases. It also offers flu, rheumatism, and anti-infectious drugs. The company was founded on January 27, 1995 and is headquartered in Guiyang, China.

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Key Stats and Financials As of 2019
Market Capitalization
$82.4B
Total Enterprise Value
$54.2B
Earnings Per Share
$0.15
EBITDAMargin
26.54%
Enterprise Value / Sales
16.13x
Enterprise Value EBITDAOperating
60.78x
TEVNet Income
69.85x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
28.43%
Revenue
$3.36B
Net Profit
$776M
EBITDA
$892M
Total Debt
$61.2M
Total Equity
$3.63B
Suppliers
TESARO, Inc. Pharmaceuticals | Waltham, MA

TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon O. Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA.

Zhejiang Canaan Technology Co., Ltd. Hospitals & Patient Services | Wenzhou, China

Zhejiang Canaan Technology Co., Ltd. engages in the manufacture and sale of solid dosage technology equipments. Its products include mixer and granulator series, fluid-bed processor series, mill cum sifter series, blender series, pharma lifter series, coater series, bin washer series, container, roller compactor and bin & drum series. The company was founded by Fang Heng Zhi and Fang Zhi Yi on December 15, 2008 and is headquartered in Wenzhou, China.

Hangzhou Zhongya Machinery Co. Ltd. Wholesale: Industrial Products & Manufacturing | Hangzhou, China

Hangzhou Zhongya Machinery Co. Ltd. is engaged in the manufacturing and selling of food-packing machine. Its products include cup filling equipment, bottle filling equipment, bottle blow equipment, downstream packaging, and integrated lines solutions. The company was founded by Shi Zhong Wei on February 8, 1999 and is headquartered in Hangzhou, China.

Competitors
Sino Biopharmaceutical Ltd. Pharmaceuticals - Hong Kong

Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.

Livzon Pharmaceutical Group, Inc. Pharmaceuticals - Zhuhai, China

Livzon Pharmaceutical Group, Inc. engages in the research and development, production, and distribution of pharmaceutical products. It offers drug preparation products, bulk medicines and intermediates, and diagnostic reagents and equipment. The company was founded on March 1, 1992 and is headquartered in Zhuhai, China.

Sichuan Kelun Pharmaceutical Co., Ltd. Pharmaceuticals - Chengdu, Chn

Sichuan Kelun Pharmaceutical Co., Ltd. engages in research, development, manufacture, and sale of pharmaceutical products. Its products include large volume injection (infusion), small capacity injection (water injection), sterile powder injection, tablets, capsules, granules, oral solution, and peritoneum. It also provides dialysate and antibiotic intermediates, raw materials, pharmaceutical packaging materials, medical equipment, and other medical products. The company was founded by Ge Xin Liu in 1996 and is headquartered in Chengdu, China.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jiangsu Hengrui Medicine Co., Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jiangsu Hengrui Medicine Co., Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Jiangsu Hengrui Medicine Co., Ltd..